Last reviewed · How we verify
NCT04235621
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
trial testing FSGS/TR-MCD in Glomerulosclerosis, Focal Segmental in 20 participants. Terminated before completion.
27 May 2020
Quick facts
| Lead sponsor | Goldfinch Bio, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 20 December 2019 |
| Primary completion | 27 May 2020 |
| Estimated completion | 27 May 2020 |
| Sites | 18 locations across United States |
Drugs / interventions tested
- FSGS/TR-MCD
- Diabetic Nephropathy (DN)
Conditions studied
- Glomerulosclerosis, Focal Segmental — all drugs for Glomerulosclerosis, Focal Segmental →
- Minimal Change Disease — all drugs for Minimal Change Disease →
- Diabetic Nephropathies — all drugs for Diabetic Nephropathies →
Sponsor
Goldfinch Bio, Inc. — full company profile →
Who can join
18 and older, any sex, with Glomerulosclerosis, Focal Segmental or Minimal Change Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04235621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glomerulosclerosis, Focal Segmental
Currently open trials in the same condition.
- NCT05505500 — Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. · recruiting
- NCT03949972 — The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) · recruiting
Other Goldfinch Bio, Inc. trials
Trials by the same sponsor.
- NCT04950114 — An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases · Phase 2 · terminated
- NCT04880291 — First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes · Phase 1 · completed
- NCT04387448 — A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatm · Phase 2 · terminated
- NCT03970122 — FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04235621 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goldfinch Bio, Inc.
- Last refreshed: 20 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04235621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing